ColonoscopyNCT07419204
Tissue Cytomegalovirus Viral Load and Associated Factors in Pediatric Patients Undergoing Colonoscopy
An observational study of Colonoscopy and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), run by Gazi University at 1 site in Turkey (Türkiye).
Trial summary
Introduction and Objectives Patients diagnosed with Inflammatory Bowel Disease (IBD) carry a significantly elevated risk for opportunistic infections and the reactivation of latent pathogens, most notably Cytomegalovirus (CMV). Read more about this study
- Who is it for?
- Ages 1 month to 18 years
- Conditions the study is for
- Colonoscopy, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), CMV
- What is being tested?
- Colonoscopy after bowel cleansing
- How many people
- 139 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 May 2022to 31 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Study population: Pediatric patients who underwent colonoscopic evaluation at the Pediatric Gastroenterology Endoscopy Unit between May 2022 and March 2024.
Who may be able to join
- -Pediatric patients undergoing colonoscopy for any clinical indication were eligible for inclusion after obtaining written informed consent.
Who cannot join
- Patients with insufficient bowel preparation for a high-quality colonoscopic examination.
- Biopsy Contraindications: Individuals with medical conditions precluding biopsy, such as bleeding diathesis.
- Non-Participation: Patients or guardians who declined to participate in the study.
- Children who were undergoing treatment for CMV disease
- Children who were receiving antiviral therapy (e.g. acyclovir)
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gazi University Faculty of Medicine
Ankara, Ankara, 06500
About this study
Official title: Investigation of Tissue Cytomegalovirus (CMV) Status Via Polymerase Chain Reaction and Serological Tests in Patients Undergoing Colonoscopy and Intestinal Biopsy
Introduction and Objectives Patients diagnosed with Inflammatory Bowel Disease (IBD) carry a significantly elevated risk for opportunistic infections and the reactivation of latent pathogens, most notably Cytomegalovirus (CMV). CMV reactivation in the colonic mucosa can exacerbate underlying IBD, leading to poor clinical outcomes and resistance to standard immunosuppressive therapies.
This prospective study was designed with a multi-faceted objective:
Read more
To evaluate and quantify the CMV viral load within the intestinal tissues of a pediatric cohort, comprising both IBD and non-IBD control groups.
To identify specific clinical and biological factors associated with increased CMV detection.
To establish potential diagnostic threshold values for CMV viral load in the colonic mucosa, with a primary focus on Ulcerative Colitis (UC) patients-where CMV colitis is most prevalent-as well as patients with other intestinal pathologies.
To perform a comparative analysis of diagnostic modalities, specifically evaluating the diagnostic value of histopathology, serum Cytomegalovirus-Polymerase Chain Reaction (CMV-PCR), and tissue CMV-PCR.
- Methodology and Procedural Framework The research was conducted at the Pediatric Gastroenterology Endoscopy Unit between May 2022 and March 2024. The study population consisted of pediatric patients undergoing scheduled colonoscopies.
Biopsy Protocol: During the endoscopic procedure, two biopsy samples were systematically obtained from the rectal mucosa. For patients presenting with mucosal ulcers, samples were extracted directly from the ulcerated site; in patients with macroscopically normal mucosa, samples were taken from standard rectal tissue.
Contamination Prevention: To ensure molecular integrity and prevent cross-contamination, separate forceps were utilized for samples intended for PCR analysis versus those intended for histopathology.
Laboratory Analysis: Concurrently, venous blood samples were collected to analyze CMV serology (anti-CMV Immunoglobulin G [IgG] / Immunoglobulin M [IgM]) and serum CMV-PCR. In cases of IgM positivity, CMV IgG avidity tests were performed to distinguish between primary infection and reactivation.
Diagnostic Criteria: A diagnosis of CMV colitis was established based on clinical symptoms, histopathological evidence (Hematoxylin and Eosin [HE] staining and Immunohistochemistry [IHC]), and a serum CMV-PCR threshold of ≥1000 copies/mL.
- Molecular and Histopathological Techniques Deoxyribonucleic Acid (DNA) Extraction: Tissue DNA was extracted using the QIAamp DNA Mini Kit, involving overnight incubation at 56°C for complete tissue digestion. Plasma DNA extraction was automated via the QIAsymphony SP platform. Internal controls were used in every run to validate extraction efficiency.
Real-Time Polymerase Chain Reaction (Real-Time PCR): Amplification targeted a 105-bp region of the CMV genome using the Artus CMV QS-RGQ Kit. The assay provided a wide linear range (79.4 to 1×10⁸ copies/mL) with a high analytical sensitivity of 42.5 copies/mL. Results were reported as copies/mL for blood and copies/mg for tissue.
Immunohistochemistry (IHC): Four-micrometer tissue sections were analyzed for CMV expression using the Ventana Benchmark XT platform. Nuclear staining was the primary indicator for CMV positivity, with known positive colon mucosa serving as the control.
- Statistical Analysis Data were analyzed using IBM SPSS Statistics Version 20.0. The normality of the data was verified using Shapiro-Wilk tests and visualization tools (histograms and Q-Q plots).
Comparative Statistics: Categorical variables were assessed via Chi-square tests. Continuous variables were analyzed using Student's t-test (parametric) or the Mann-Whitney U test (non-parametric).
Correlations: Relationships between viral loads and clinical variables were evaluated using Spearman's correlation and point-biserial correlation.
A p-value of <0.05 was maintained as the threshold of statistical significance.
Read the detailed description
Detailed Description Patients with inflammatory bowel disease (IBD) are at increased risk of infections and reactivation of latent pathogens. This study aimed to evaluate Cytomegalovirus (CMV) viral load in the intestinal tissues of pediatric patients, including both IBD and non-IBD groups, and to identify factors associated with increased CMV detection. The study also aimed to establish potential threshold values for CMV viral load in the colonic mucosa, primarily in Ulcerative Colitis (UC) patients, where CMV colitis is more frequently observed, as well as in patients with other intestinal diseases. Finally, diagnostic methods-including histopathology, serum CMV-Polymerase Chain Reaction (CMV-PCR), and tissue CMV-PCR-were compared in terms of diagnostic value.
This prospective study was conducted on pediatric patients who underwent colonoscopy at the Pediatric Gastroenterology Endoscopy Unit between May 2022 and March 2024.
During colonoscopy, two biopsy samples were obtained from the rectal mucosa. In patients with rectal ulcers, biopsies were obtained from the ulcerated area; in patients without ulcers, biopsies were taken from macroscopically normal tissue. Two biopsies were collected from each site: one for tissue CMV-PCR analysis and one for histopathological examination. To prevent contamination, separate forceps were used for samples intended for CMV-PCR.
Concurrent blood samples were analyzed by CMV-PCR and serology (anti-CMV IgG and anti-CMV IgM). CMV IgG avidity was assessed in IgM-positive patients. CMV colitis was diagnosed based on clinical and histopathological findings (IHC and HE staining), along with serum CMV-PCR positivity ≥1000 copies/mL.
2.1. CMV-Deoxyribonucleic Acid (DNA) Extraction from Biopsy Samples Deoxyribonucleic Acid extraction from biopsy samples was performed using the QIAamp DNA Mini Kit [Qiagen, Düsseldorf, Germany] following the manufacturer's instructions. Approximately 25 mg of biopsy tissue was combined with 180 µL of tissue lysis buffer and 20 µL of proteinase K and then vortexed. Samples were incubated overnight at 56°C until the tissue was completely digested. Subsequently, 200 µL of tissue lysis buffer was added, and the samples were incubated at 70°C for 10 minutes. After adding 200 µL ethanol, the mixture was vortexed, centrifuged, and transferred to spin columns. Following washing and centrifugation, DNA was eluted according to the manufacturer's protocol.
2.2. CMV-DNA Extraction from Plasma Samples Deoxyribonucleic Acid extraction from plasma samples was performed using the QIAsymphony DSP Virus/Pathogen Midi Kit [QIAGEN, Germany] on the QIAsymphony SP instrument [QIAGEN, Germany] according to the manufacturer's guidelines. An internal control was included in each sample to assess the extraction efficiency.
2.3. CMV-DNA Amplification Amplification of the extracted CMV DNA was performed using an Artus CMV QS-RGQ Kit [Qiagen, Germany] on a Rotor-Gene Q instrument [Qiagen, Germany]. This kit enables the specific amplification of a 105-bp region of the CMV genome. For each patient, a 25 µL master mix and 5 µL magnesium solution were prepared, and 30 µL of the mixture was transferred into amplification tubes and combined with patient-derived isolates. The samples were loaded onto a Rotor-Gene Q instrument. Each run included four quantification standards and a negative control to detect potential contamination. Viral loads in the blood and tissue samples were reported as copies/mL and copies/mg, respectively. The analytical sensitivity of the assay was 42.5 copies/mL, with a linear range of 79.4 to 1×10⁸ copies/mL.
2.4. Histopathological Evaluation Four-micrometer-thick sections of formalin-fixed paraffin-embedded tissue were mounted on positively charged slides. CMV expression [Cell Marque, clone 8B1.2 1G5.2 \& 2D4.2, 1:500 dilution] was assessed using the Ultraview Universal DAB Detection Kit through a streptavidin-biotin triple indirect immunoperoxidase method on the automated Ventana Benchmark XT platform. Colon mucosa, which is known to be CMV-positive, served as a positive control. Nuclear staining of cells was considered indicative of CMV expression, and biopsies displaying this expression were interpreted as positive.
2.5. StatisticalAnalysis All collected data were recorded in the study form and analyzed using IBM SPSS Statistics version 20.0 [Chicago, IL, USA]. The normality of continuous and discrete variables was assessed using the Shapiro-Wilk test, histograms, and Q-Q plots. Descriptive statistics were presented as mean ± standard deviation [SD] or median [interquartile range, IQR] for continuous variables and as frequency [percentage] for categorical variables. Categorical variables were compared using the Chi-square test, whereas continuous variables were evaluated using Student's t-test for normally distributed data and the Mann-Whitney U test for non-normally distributed data. Spearman's correlation analysis was applied for correlations between non-normally distributed continuous variables, and point-biserial correlation was used for correlations between dichotomous and continuous variables. A significance level of p < 0.05 was considered statistically significant, with a critical alpha value set at 0.05.
- Being tested
- Colonoscopy after bowel cleansing
- Keywords
- inflammatory bowel disease, Crohn's disease, Ulcerative colitis, CMV, histopathology, PCR
- Medical subject headings
- Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Colonoscopy after bowel cleansingDiagnostic test
Also called polymerase chain reaction, CMV histopathology
This is the first prospective study to concurrently examine and compare CMV PCR levels in colonic tissue and associated histopathological changes between pediatric patients with and without Inflammatory Bowel Disease (IBD)
| Study group | Role | What they receive |
|---|---|---|
| The patients who underwent colonoscopy at the Pediatric Gastroenterology Department. | Biopsy specimens were obtained from the intestinal mucosa of pediatric patients who underwent colonoscopy for any clinical indication within the specified period. Receives: Diagnostic Test: Colonoscopy after bowel cleansing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tissue and serum CMV Viral Load
Cytomegalovirus Polymerase chain reaction levels were detected in both blood and tissue samples across the entire patient population
Measured: 1,5 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start2 May 2022
- Primary completion31 Jan 2024
- Study completion31 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ColonoscopyStudies of the same condition, open and under way.
- More trials run by Gazi UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 139 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gazi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ödül EGRİTAS, Gazi University
- Investigators
- Odul OE Egritas Gurkan, Professor, Principal investigator, Gazi Universty Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07419204
- Sponsor's protocol ID
- GaziUD
- Other IDs
- Gazi University
- Status last verified
- Feb 2026
- First submitted
- 9 Feb 2026
- Last updated
- 18 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data that underlie the results reported in this article will be shared with researchers who provide a methodologically appropriate reason and proposal.
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Tissue Cytomegalovirus (CMV) Status Via Polymerase Chain Reaction and Serological Tests in Patients Undergoing Colonoscopy and Intestinal Biopsy
- ClinicalTrials.gov ID
- NCT07419204
- Acronym / sponsor ID
- GaziUD
- Keywords
- inflammatory bowel disease, Crohn's disease, Ulcerative colitis, CMV, histopathology, PCR
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 139 participants (actual)
- Lead sponsor
- Gazi UniversityUniversity, hospital or other
- Study start
- 2 May 2022 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 31 Jan 2024 (actual)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction and Objectives Patients diagnosed with Inflammatory Bowel Disease (IBD) carry a significantly elevated risk for opportunistic infections and the reactivation of latent pathogens, most notably Cytomegalovirus (CMV). CMV reactivation in the colonic mucosa can exacerbate underlying IBD, leading to poor clinical outcomes and resistance to standard immunosuppressive therapies.
This prospective study was designed with a multi-faceted objective:
To evaluate and quantify the CMV viral load within the intestinal tissues of a pediatric cohort, comprising both IBD and non-IBD control groups.
To identify specific clinical and biological factors associated with increased CMV detection.
To establish potential diagnostic threshold values for CMV viral load in the colonic mucosa, with a primary focus on Ulcerative Colitis (UC) patients-where CMV colitis is most prevalent-as well as patients with other intestinal pathologies.
To perform a comparative analysis of diagnostic modalities, specifically evaluating the diagnostic value of histopathology, serum Cytomegalovirus-Polymerase Chain Reaction (CMV-PCR), and tissue CMV-PCR.
- Methodology and Procedural Framework The research was conducted at the Pediatric Gastroenterology Endoscopy Unit between May 2022 and March 2024. The study population consisted of pediatric patients undergoing scheduled colonoscopies.
Biopsy Protocol: During the endoscopic procedure, two biopsy samples were systematically obtained from the rectal mucosa. For patients presenting with mucosal ulcers, samples were extracted directly from the ulcerated site; in patients with macroscopically normal mucosa, samples were taken from standard rectal tissue.
Contamination Prevention: To ensure molecular integrity and prevent cross-contamination, separate forceps were utilized for samples intended for PCR analysis versus those intended for histopathology.
Laboratory Analysis: Concurrently, venous blood samples were collected to analyze CMV serology (anti-CMV Immunoglobulin G [IgG] / Immunoglobulin M [IgM]) and serum CMV-PCR. In cases of IgM positivity, CMV IgG avidity tests were performed to distinguish between primary infection and reactivation.
Diagnostic Criteria: A diagnosis of CMV colitis was established based on clinical symptoms, histopathological evidence (Hematoxylin and Eosin [HE] staining and Immunohistochemistry [IHC]), and a serum CMV-PCR threshold of ≥1000 copies/mL.
- Molecular and Histopathological Techniques Deoxyribonucleic Acid (DNA) Extraction: Tissue DNA was extracted using the QIAamp DNA Mini Kit, involving overnight incubation at 56°C for complete tissue digestion. Plasma DNA extraction was automated via the QIAsymphony SP platform. Internal controls were used in every run to validate extraction efficiency.
Real-Time Polymerase Chain Reaction (Real-Time PCR): Amplification targeted a 105-bp region of the CMV genome using the Artus CMV QS-RGQ Kit. The assay provided a wide linear range (79.4 to 1×10⁸ copies/mL) with a high analytical sensitivity of 42.5 copies/mL. Results were reported as copies/mL for blood and copies/mg for tissue.
Immunohistochemistry (IHC): Four-micrometer tissue sections were analyzed for CMV expression using the Ventana Benchmark XT platform. Nuclear staining was the primary indicator for CMV positivity, with known positive colon mucosa serving as the control.
- Statistical Analysis Data were analyzed using IBM SPSS Statistics Version 20.0. The normality of the data was verified using Shapiro-Wilk tests and visualization tools (histograms and Q-Q plots).
Comparative Statistics: Categorical variables were assessed via Chi-square tests. Continuous variables were analyzed using Student's t-test (parametric) or the Mann-Whitney U test (non-parametric).
Correlations: Relationships between viral loads and clinical variables were evaluated using Spearman's correlation and point-biserial correlation.
A p-value of <0.05 was maintained as the threshold of statistical significance.
Detailed description
Detailed Description Patients with inflammatory bowel disease (IBD) are at increased risk of infections and reactivation of latent pathogens. This study aimed to evaluate Cytomegalovirus (CMV) viral load in the intestinal tissues of pediatric patients, including both IBD and non-IBD groups, and to identify factors associated with increased CMV detection. The study also aimed to establish potential threshold values for CMV viral load in the colonic mucosa, primarily in Ulcerative Colitis (UC) patients, where CMV colitis is more frequently observed, as well as in patients with other intestinal diseases. Finally, diagnostic methods-including histopathology, serum CMV-Polymerase Chain Reaction (CMV-PCR), and tissue CMV-PCR-were compared in terms of diagnostic value.
This prospective study was conducted on pediatric patients who underwent colonoscopy at the Pediatric Gastroenterology Endoscopy Unit between May 2022 and March 2024.
During colonoscopy, two biopsy samples were obtained from the rectal mucosa. In patients with rectal ulcers, biopsies were obtained from the ulcerated area; in patients without ulcers, biopsies were taken from macroscopically normal tissue. Two biopsies were collected from each site: one for tissue CMV-PCR analysis and one for histopathological examination. To prevent contamination, separate forceps were used for samples intended for CMV-PCR.
Concurrent blood samples were analyzed by CMV-PCR and serology (anti-CMV IgG and anti-CMV IgM). CMV IgG avidity was assessed in IgM-positive patients. CMV colitis was diagnosed based on clinical and histopathological findings (IHC and HE staining), along with serum CMV-PCR positivity ≥1000 copies/mL.
2.1. CMV-Deoxyribonucleic Acid (DNA) Extraction from Biopsy Samples Deoxyribonucleic Acid extraction from biopsy samples was performed using the QIAamp DNA Mini Kit [Qiagen, Düsseldorf, Germany] following the manufacturer's instructions. Approximately 25 mg of biopsy tissue was combined with 180 µL of tissue lysis buffer and 20 µL of proteinase K and then vortexed. Samples were incubated overnight at 56°C until the tissue was completely digested. Subsequently, 200 µL of tissue lysis buffer was added, and the samples were incubated at 70°C for 10 minutes. After adding 200 µL ethanol, the mixture was vortexed, centrifuged, and transferred to spin columns. Following washing and centrifugation, DNA was eluted according to the manufacturer's protocol.
2.2. CMV-DNA Extraction from Plasma Samples Deoxyribonucleic Acid extraction from plasma samples was performed using the QIAsymphony DSP Virus/Pathogen Midi Kit [QIAGEN, Germany] on the QIAsymphony SP instrument [QIAGEN, Germany] according to the manufacturer's guidelines. An internal control was included in each sample to assess the extraction efficiency.
2.3. CMV-DNA Amplification Amplification of the extracted CMV DNA was performed using an Artus CMV QS-RGQ Kit [Qiagen, Germany] on a Rotor-Gene Q instrument [Qiagen, Germany]. This kit enables the specific amplification of a 105-bp region of the CMV genome. For each patient, a 25 µL master mix and 5 µL magnesium solution were prepared, and 30 µL of the mixture was transferred into amplification tubes and combined with patient-derived isolates. The samples were loaded onto a Rotor-Gene Q instrument. Each run included four quantification standards and a negative control to detect potential contamination. Viral loads in the blood and tissue samples were reported as copies/mL and copies/mg, respectively. The analytical sensitivity of the assay was 42.5 copies/mL, with a linear range of 79.4 to 1×10⁸ copies/mL.
2.4. Histopathological Evaluation Four-micrometer-thick sections of formalin-fixed paraffin-embedded tissue were mounted on positively charged slides. CMV expression [Cell Marque, clone 8B1.2 1G5.2 \& 2D4.2, 1:500 dilution] was assessed using the Ultraview Universal DAB Detection Kit through a streptavidin-biotin triple indirect immunoperoxidase method on the automated Ventana Benchmark XT platform. Colon mucosa, which is known to be CMV-positive, served as a positive control. Nuclear staining of cells was considered indicative of CMV expression, and biopsies displaying this expression were interpreted as positive.
2.5. StatisticalAnalysis All collected data were recorded in the study form and analyzed using IBM SPSS Statistics version 20.0 [Chicago, IL, USA]. The normality of continuous and discrete variables was assessed using the Shapiro-Wilk test, histograms, and Q-Q plots. Descriptive statistics were presented as mean ± standard deviation [SD] or median [interquartile range, IQR] for continuous variables and as frequency [percentage] for categorical variables. Categorical variables were compared using the Chi-square test, whereas continuous variables were evaluated using Student's t-test for normally distributed data and the Mann-Whitney U test for non-normally distributed data. Spearman's correlation analysis was applied for correlations between non-normally distributed continuous variables, and point-biserial correlation was used for correlations between dichotomous and continuous variables. A significance level of p < 0.05 was considered statistically significant, with a critical alpha value set at 0.05.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The patients who underwent colonoscopy at the Pediatric Gastroenterology Department. | – | Diagnostic Test: Colonoscopy after bowel cleansingBiopsy specimens were obtained from the intestinal mucosa of pediatric patients who underwent colonoscopy for any clinical indication within the specified period. |
Who may qualify
- Ages
- 1 month to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Study population: Pediatric patients who underwent colonoscopic evaluation at the Pediatric Gastroenterology Endoscopy Unit between May 2022 and March 2024.
Key inclusion criteria (1 listed)
- -Pediatric patients undergoing colonoscopy for any clinical indication were eligible for inclusion after obtaining written informed consent.
Key exclusion criteria (5 listed)
- Patients with insufficient bowel preparation for a high-quality colonoscopic examination.
- Biopsy Contraindications: Individuals with medical conditions precluding biopsy, such as bleeding diathesis.
- Non-Participation: Patients or guardians who declined to participate in the study.
- Children who were undergoing treatment for CMV disease
- Children who were receiving antiviral therapy (e.g. acyclovir)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Colonoscopy after bowel cleansingAlso: polymerase chain reaction, CMV histopathologyThis is the first prospective study to concurrently examine and compare CMV PCR levels in colonic tissue and associated histopathological changes between pediatric patients with and without Inflammatory Bowel Disease (IBD) | Diagnostic test | The patients who underwent colonoscopy at the Pediatric Gastroenterology Department. |
Primary outcome
Tissue and serum CMV Viral Load
Time frame: 1,5 year
Cytomegalovirus Polymerase chain reaction levels were detected in both blood and tissue samples across the entire patient population
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data that underlie the results reported in this article will be shared with researchers who provide a methodologically appropriate reason and proposal.
Related trials for Colonoscopy
Not yet recruiting
Effect of Box Breathing Exercise on Anxiety, Pain, and Pulmonary Function Tests in Patients Undergoing Colonoscopy
Colonoscopy
Not yet recruiting
HFNC vs Conventional Oxygen During Gastrocolonoscopy in Elderly Patients
Hypoxemia, Eldery People
RecruitingObservational study
The French Gut-colo
Patients Aged 50-75 and Requiring Colonoscopy
Not yet recruiting
Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy
Colonoscopy, Bowel Preparation
Recruiting
Comparison of Electrolyte Beverages and Water as Solvents for Bowel Preparation
Bowel Preparation Before Colonoscopy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Odul OE Egritas Gurkan, Professor principal investigator
Gazi Universty Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colonoscopy and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), run by Gazi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tissue and serum CMV Viral Load (time frame: 1,5 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2026; AzTrials last refreshed its copy on 8 Nov 2026.